CytoDyn Inc (OTCMKTS:CYDY) Administers Leronlimab Drug to First Patient in Major Phase 3 Covid-19 Trial
CytoDyn Inc (OTCMKTS:CYDY) has made a statement regarding its treatment of the first patient with its much-touted about drug candidate leronlimab (Vyrologix or PRO 140), in a crucial Phase 3 Covid-19 trial in Brazil. The treatment is for patients with severe symptoms. After the enrolment of 245 patients (40% of the total number in the trial), an interim analysis will be conducted after 28 days. The trial is being conducted…









